Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Идёт Беларусь

4631

Safety and Performance Evaluation of the AccuCinch® Ventricular Restoration System for the Treatment of Heart Failure With or Without Functional Mitral Regurgitation Due to Dilated Ischemic or Non-Ischemic Cardiomyopathy - The CorCinch-EU Study

Номер протокола4631
ФазаФаза не указана
Участников по плану — во всех странах исследования132
Сроки15.01.2019 — 01.12.2027
Начало: 15 января 2019Окончание: 1 декабря 2027
Пройдено 88% планового срока

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Исследование идёт.
  • Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 132 чел. во всех странах исследования.
  • Центров в реестре: 1 в одном городе. Список — ниже на странице.
  • Плановое окончание — 12.2027.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возрастот 18 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 12 · невключение: 35

Критерии включения

  • Age ≥ 18 years
  • Subjects who present with heart failure with or without functional mitral regurgitation due to dilated cardiomyopathy of ischemic or non-ischemic etiology
  • For subjects with FMR, severity of FMR: ≥ Moderate 2+
  • For subjects without FMR, LVEDD ≥ 55 mm
  • Ejection Fraction: ≥20 to ≤40%
  • Symptom Status: NYHA II-IVa
  • Patients to be considered for the present study will be required to have received all appropriate guidelines-recommended therapies for at least 3 months prior to the enrollment with stable doses of drugs for at least 1 month.
  • Surgical risk:
  • For patients with FMR only: the Heart Team must assess as high-risk and may utilize risk score or comorbidities to demonstrate high risk features. High risk for mitral valve surgery is defined utilizing established risk scores (STS, Euro-Score II) in conjunction with comorbidities as recommended by MVARC (frailty index; major organ system compromise not to be improved postoperatively; procedure specific impediments) (MVARC Part 1)
  • For all patients: Subject is eligible for cardiac surgery (namely, the patient is in a condition that allows a potential conversion to open surgery in case of procedural complications). This criterion adds a safety level for the patients
  • Completion of all qualifying diagnostic and functional tests and agrees to comply with study follow-up schedule
  • Patients required to have an ICD are required to have ICD implant at least 1 month prior to enrollment

Критерии невключения

  • Life expectancy <1 yr due to noncardiac conditions
  • NYHA functional class IVb or ACC/AHA stage D heart failure
  • Hypotension (systolic pressure <90 mm Hg) or requirement for inotropic support or mechanical hemodynamic support
  • Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or nonischemic etiology
  • Fixed pulmonary artery systolic pressure >70 mm Hg
  • Physical evidence of right-sided congestive heart failure with echocardiographic evidence of moderate or severe right ventricular dysfunction
  • Mitral valve anatomy which may preclude proper device treatment
  • Mitral valve area <4.0 cm2 (if new device therapy may further decrease the mitral orifice area)
  • Any prior mitral valve surgery or transcatheter mitral valve procedure
  • Stroke or transient ischemic event within 30 days
  • Modified Rankin Scale ≥ 4 disability
  • Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months
  • Untreated clinically significant coronary artery disease requiring revascularization
  • Severe symptomatic carotid stenosis (>70% by ultrasound).
  • Myocardial infarction ≤ 30 days
  • Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days
  • Tricuspid valve disease requiring surgery or severe tricuspid regurgitation (per ASE guidelines; core lab assessment)
  • Aortic valve disease requiring surgery
  • Moderate or severe aortic valve stenosis or regurgitation
  • Aortic valve prosthesis
  • Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile aortic atheroma, intracardiac mass, thrombus, or vegetation
  • Need for any cardiovascular surgery (other than for MV disease)
  • Active endocarditis
  • Anatomical pathology/constraints preventing appropriate access/implant of the AccuCinch System (e.g., femoral arteries will not support an 20F system)
  • Known allergy to nickel, polyester, or polyethylene
  • Active infections requiring current antibiotic therapy
  • Subjects in whom transesophageal echocardiography is contraindicated
  • Renal insufficiency (i.e., eGFR of <30ml/min/1.73m2; Stage 4 or 5 CKD)
  • Subjects in whom anticoagulation or antiplatelet therapy is contraindicated
  • Any prior true anaphylactic reaction to contrast agents; defined as known anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that cannot be adequately pre-medicated prior to procedure.
  • Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter defibrillator within 1 month
  • Absence of CRT with class I indication criteria for biventricular pacing (left bundle branch block pattern and QRS duration ≥150 ms)
  • Subjects on high dose steroids or immunosuppressant therapy
  • Any condition making it unlikely the patient will be able to complete all protocol procedures (including compliance with guideline directed medical therapy) and follow-up visits
  • Patient is unable or unwilling to sign written patient information sheet and informed consent form before study enrollment. This study excludes vulnerable populations as defined in protocol section 18.

Источник: ClinicalTrials.gov, NCT03183895 · запись обновлена в реестре 29 января 2025.

Дизайн и результаты

ДизайнОткрытое (без ослепления), одна группа; цель — лечение
Участников по плану (все страны)132
Результатыбудут после окончания
Что измеряют — первичные конечные точки (1), вторичных — 6
  • Safety outcome: 30-day major adverse events (MAEs) — 30-day

Цель исследования

This is prospective, non-randomized, single-arm, international, multicenter, clinical safety and performance clinical investigation to evaluate the AccuCinch® Ventricular Repair System for the treatment of heart failure, with or without functional mitral regurgitation due to dilated ischemic or non-ischemic cardiomyopathy

Где проходит

1 центр в 1 городе

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT03183895 Официальный реестр (США) · загружено 9 ноября 2026
    Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.